A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

Clinical trial NCT05557045 · RECRUITING

Trial details

NCT number: NCT05557045
Sponsor: Jazz Pharmaceuticals
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Cancer Metastatic Cancer Solid Tumor

Start date: 2022-10-10
Primary completion: 2028-04-01
Enrollment: 332

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.